Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Moderna

A personalized vaccine developed by Moderna (MRNA) and Merck (MRK) showed significant positive results in treating skin cancer in high risk patients.

Moderna-Merck Vaccine for Skin Cancer Shows Positive Results; Moderna Stock Jumps

Moderna Inc.'s stock MRNA, +0.72% soared 7% early Thursday, after the biotech and partner Merck MRK, +2.65% announced positive data from a mid-stage trial of Moderna's mRNA-4157 in combination with Merck's blockbuster cancer drug Keytruda in patients with resected high-risk melanoma (stage III/IV). The companies said after about three years, the combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62%, compared with Keytrua alone.

Moderna's stock rallies 7.9% after announcing positive data in trial of melanoma treatment combined with Merck's Keytruda

An experimental messenger RNA cancer vaccine developed by Moderna and Merck & Co paired with Merck's Keytruda cut the chance of recurrence or death from melanoma by half after three years, showing that benefits demonstrated a year ago have held up over time.

Benefits of Moderna and Merck melanoma vaccine plus Keytruda extend to three years

Moderna's Merck-partnered cancer vaccine reduced the risk of relapse or death by 49% in melanoma patients. Moderna stock could jump.

Moderna's Cancer Vaccine Cuts Risk Of Relapse, Death By 49%; Will Shares Jump?

At a median planned follow-up of approximately three years, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510 [95% CI, 0.288-0.906]; one-sided nominal p=0.0095) and the risk of distant metastasis or death by 62% (HR=0.384 [95% CI, 0.172-0.858]; one-sided nominal p= 0.0077) compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete resection Data builds on the primary analysis reported at AACR and ASCO in 2023, which showed that mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% and reduced the risk of distant metastasis or death by 65% at a median planned follow-up of approximately two years Companies have initiated Phase 3 studies in the adjuvant setting in patients with high-risk melanoma and non-small cell lung cancer and plan to rapidly expand to additional tumor types CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / December 14, 2023/ Moderna, Inc. (NASDAQ:MRNA) and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced follow-up data from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti-PD-1 therapy, in patients with resected high-risk melanoma (stage III/IV) following complete resection. In this planned analysis occurring with a median follow-up of approximately three years, adjuvant treatment with mRNA-4157 (V940) in combination with KEYTRUDA continued to demonstrate a clinically meaningful improvement in recurrence-free survival (RFS), reducing the risk of recurrence or death by 49% (HR=0.510 [95% CI, 0.288-0.906]; one-sided nominal p=0.0095) compared with KEYTRUDA alone.

Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Comp

Moderna's personalized cancer vaccine is being used with a Merck immunotherapy drug to fight melanoma cancer.

Moderna Reports More Promising Data on Its Cancer Treatment

Eli Lilly

Health care stocks to check out in the stock market now.

What Are The Best Stocks To Invest In Now? 2 Health Care Stocks To Watch

C4 Therapeutics

C4 Therapeutics Inc shares surged 93% to $2.28 in early trading on Tuesday after the clinical-stage biopharmaceutical company announced an exclusive license and collaboration agreement with Merck to develop degrader-antibody conjugates (DACs), an emerging modality designed to selectively target and neutralize disease-causing proteins in cancer cells.  C4 said it will receive a $10 million upfront payment and is eligible to receive milestone payments totaling about $600 million, as well as tiered royalties on future sales.

C4 Therapeutics stock soars on Merck partnership, license deal

The combination of Merck's (MRK) Keytruda and Eisai's Lenvima for the first-line treatment of advanced/recurrent endometrial carcinoma fails to meet dual primary endpoints in late-stage study.

Merck's (MRK) Keytruda, Lenvima Endometrial Cancer Study Fails

Amgen

AstraZeneca

Bristol-Myers

Gilead Sciences

Novo Nordisk

Novartis

Pfizer

Sanofi

This biotech giant remains a top stock for investors to buy and pays a solid 3.13% dividend.

6 Health Care Dividend Stocks To By Hand Over Fist

Moderna and Merck & Co said on Monday they have started a late-stage trial of their experimental personalized mRNA cancer treatment in combination with blockbuster drug Keytruda for patients with a type of lung cancer.

Moderna, Merck begin late-stage study for mRNA cancer therapy

RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Moderna Initiate INTerpath-002 Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA for Certain Types of Resected NSCLC.

Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for BRAVECTO® (fluralaner) 150 mg/ml powder and solvent for suspension for injection for dogs. The CVMP recommends the product for approval for the treatment and persistent killing o.

Merck Animal Health Receives Positive CVMP Opinion for an Injectable Formulation of BRAVECTO® (Fluralaner) for Use in Dogs

Chevron

Jefferies Financial Group Inc

Republic Services

Southern Company

Simon Property Group

This integrated giant is safer for investors looking to get positioned in the energy sector, has backed up some, and now yields a strong 4.17% dividend.

Dividend Lovers Betting Big on 6 Goldman Sachs Top Conviction List Picks for 2024

Apple

AbbVie

Broadcom

Blackrock Inc

Home Depot

Johnson & Johnson

JPMorgan Chase & Co

Coca-Cola

Mastercard

Microsoft

PepsiCo

Procter & Gamble

Schwab US Dividend Equity ETF

iShares 20+ Year Treasury Bond ETF

Texas Instruments

UnitedHealth Group

Visa

Vanguard Dividend Appreciation ETF

Vanguard High Dividend Yield ETF

Verizon

Walmart

Exxon Mobil

The economic cycles have always been with us. But the frequency of boom and bust cycles has certainly increased in the last couple of decades. If the volatility of the stock market keeps you awake at night, this article is for you. The market has been rallying for some time now. Will the bull rally continue in 2024? This article addresses some of the questions and recommends how to invest fresh capital.

How To Invest $100,000 Today In A Sleep Well Portfolio

After a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides to stop evaluating the Keytruda-Lynparza combination in metastatic squamous NSCLC.

Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study

Merck & Co Inc (NYSE:MRK) and Eisai announced Friday that their therapeutic combination targeting endometrial cancer as a first-line treatment failed to meaningfully slow the progression of the disease or improve overall survival during a late-stage trial. The Phase 3 LEAP-001 trial evaluated Merck's anti-PD-1 therapy Keytruda and Eisai's orally available multiple receptor tyrosine kinase inhibitor Lenvima as a first-line treatment in patients with endometrial cancer, a disease where cancer cells form in the lining of the uterus.

Merck-Eisai uterine cancer drug combination fails first-line treatment study

Merck & Co. Inc. MRK, -1.66% and Eisai Co. Ltd. ESALF, +3.00% said Friday that a late-stage trial of Merck's blockbuster cancer treatment Keytruda in combination with Eisai's drug Lenvima failed to meet its primary goals for treatment of certain types of endometrial cancer.

Merck and Eisai combination endometrial cancer treatment fails to meet goals in clinical trial

Merck said on Friday its experimental combination therapy being developed with partner Eisai to treat a type of cancer in the lining of the uterus failed to meet the main goals in a late-stage study.

Merck-Eisai's cancer therapy combo fails in late-stage study

RAHWAY, N.J., & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Eisai Provide Update on LEAP-001 Trial Evaluating KEYTRUDA + LENVIMA as First-Line Treatment for Advanced or Recurrent Endometrial Carcinoma.

Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Air Lease

Avient Corp

ChoiceOne Financial Services Inc

Capital Southwest

Devon Energy

Fidelity National Financial

Leidos Hld

Motorola Solutions

NexPoint Residential Trust

Prosperity Bancshares

Regency Centers

Sonic Automotive

Hanover Insurance Group

December is the last opportunity for companies to announce yearly dividend increases. 15 companies expected to raise their dividends in the upcoming week, with a focus on up-and-comers in the dividend growth space. The companies feature an average increase of 8.6% and a median increase of 4.9%.

15 Upcoming Dividend Increases

Merck & Co Inc (NYSE:MRK) announced on Thursday that its investigational lung cancer therapeutic combination of pembrolizumab (Keytruda) and vibostolimab failed to meet the goal of a mid-stage study. Vibostolimab is an investigational anti-TIGIT antibody that Merck said restores antitumor activity by blocking the TIGIT receptor from binding to its ligands (CD112 and CD155), activating T lymphocytes that assist in destroying tumor cells.

Merck cancels Phase 3 lung cancer study on disappointing interim data as separate mid-stage trial fails

News for Merck Stock (MRK)